Xinhua Silk Road: 3rd Tianjin International Shipping Industry Expo kicks off to boost win-win cooperation
To better present the development achievements of China's shipping industry and the future development trend of the global shipping industry, the expo is themed on "Shipping to the World and Navigating towards the Future, Embracing New Opportunities for Openness and Cooperation".
It focuses on the entire shipping industry chain, aiming to create the largest and most influential shipping industry event and cooperation exchange platform in China and even the world.
Lasting till June 14, the expo features nine exhibition areas involving international ports, green and smart shipping, shipping industry chains, etc., covering over 50,000 square meters, and over 20 professional activities will be held to display the development modes of the shipping industry from multiple dimensions.
Representatives from various ports, industries, and authoritative research institutions at home and abroad shared the latest trends in global port and shipping development at the opening ceremony.
Major industry achievements were also released at the opening ceremony, including the blue book on the development of Tianjin international shipping center by China Economic Information Service (CEIS), the port economic development report of Chinese seaport cities by the Transport Planning and Research Institute with the Ministry of Transport, the ESG evaluation guidelines for international shipping and logistics enterprises, etc.
Tianjin Port's operation reached its historical high level in 2024, with container throughput rising to eighth in the world and sea-rail intermodal transportation ranking third among coastal ports in China, and its land-sea connectivity and global radiation capabilities have been significantly improved, said Cao Wenzhong, president with CEIS.
According to the 2024 Xinhua-Baltic International Shipping Center Development Index, Tianjin's shipping service industry has gradually taken shape, with prominent advantages in shipping finance, Cao noted, adding that the practical exploration of the port-industry-city integration in Tianjin has great demonstration value, and the port economy has risen to become the "golden engine" for high-quality regional development.
Original link: https://en.imsilkroad.com/p/346091.html
View original content to download multimedia:https://www.prnewswire.com/news-releases/xinhua-silk-road-3rd-tianjin-international-shipping-industry-expo-kicks-off-to-boost-win-win-cooperation-302481681.html
SOURCE Xinhua Silk Road
Hashtags
- Business#TianjinInternationalShippingIndustryExpo#TISIE#Chinese#Xinhua-BalticInternationalShippingCenterDevelopmentIndex#xinhua-silk-road-3rd-tianjin-international-shipping-industry-expo-kicks-off-to-boost-win-win-cooperation-302481681.html#CEIS#PRNewswire#ChinaEconomicInformationService#CaoWenzhong#Cao
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China
Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater China Brii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance threats and continues investment in other priority pipeline assets DURHAM, N.C. and BEIJING, July 3, 2025 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," stock code: a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, today announced that it has entered into a license and technology transfer agreement with Joincare Pharmaceutical Group Industry Co., Ltd ("Joincare Group"). Joincare Group will obtain an exclusive license from Brii Bio for the research, development, and commercialization of BRII-693 in the Greater China region. Under the terms of the agreement, Joincare Group will assume full responsibility for the development, regulatory approval and commercialization of BRII-693 in Greater China. In return, Brii Bio has received an upfront payment and will receive additional development and commercial milestone payments upon certain future milestone events plus tiered royalties on net product sales. BRII-693 is a novel synthetic lipopeptide in development for the treatment of critically ill patients with multidrug- and extensively drug-resistant (MDR/XDR) gram-negative bacterial infections, particularly those caused by carbapenem-resistant Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA) and Enterobacterales (CRE). Discovered through iterative structural modifications of the polymyxin scaffold, BRII-693 was designed to enhance antibacterial potency while reducing the toxicity commonly associated with older polymyxin agents such as renal and neuro-toxicities. In phase 1 studies, BRII-693 demonstrated a favorable safety, tolerability, and PK profile in healthy non-Chinese and Chinese participants. Brii Bio received IND approval from CDE of NMPA for a Phase 1 PK bridging study in China supporting a future Phase 3 registrational trial in patients with hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. Dr. Zhi Hong, Chairman and Chief Executive Officer of Brii Bio, commented: "The growing threat of antimicrobial resistance in Greater China underscores the urgency for novel hospital antibiotics. With Joincare Group's proven capabilities in manufacturing and commercializing hospital antibiotics, we found the ideal partner to accelerate the development and commercialization of BRII-693. This partnership enables us to deliver a critical care medicine to Chinese patients facing life threatening infections." Mr. Nanqi Lin, Chief Executive Officer of Joincare Group, stated, "The Company has a long-standing track record of excellence in innovative drug research and development, underpinned by deep scientific expertise and a robust R&D platform. Driven by Brii Bio's well-established R&D system, the BRII-693 project demonstrated strong innovation and scientific rigor. Early data showing encouraging results in terms of therapeutic potential, pharmacodynamics, and pharmacokinetics, suggesting BRII-693's high potential to become a best-in-class therapy to address the critical unmet clinical needs. We are confident in the clinical prospects of BRII-693. This collaboration further strengthened Joincare Group's strategic positioning in the anti-infection disease area. We look forward to launching this asset soon, providing patients with more high-quality treatment options." About BRII-693 BRII-693 is a novel synthetic lipopeptide in development for the treatment of critically ill patients with MDR/XDR gram-negative bacterial infections, especially carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Brii Bio holds exclusive global rights to develop and commercialize BRII-693. About Brii Bio Brii Biosciences Limited ("Brii Bio", stock code: is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases, the Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B virus (HBV) infection. The Company is led by a visionary and experienced leadership team and has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. For more information, visit About Joincare Group Established in 1992, Joincare Group (Joincare Pharmaceutical Group Industry Co., Ltd) is an innovative scientific research-based integrated pharmaceutical group after many years of steady operation and rapid development. The group owns two major listed companies, Joincare and Livzon Pharmaceutical, as well as more than 20 major holding subsidiaries. The company has always adhered to the concept of scientific and technological innovation as the cornerstone, implementing a dual-driver strategy focused on innovative drugs and high-barrier complex formulation technology platforms, and has carried out rich pipeline layouts around respiratory, anti-infective, gastrointestinal, assisted reproduction, psychiatric, oncology and other areas of significant clinical needs, forming a rich and diversified product matrix and pipeline of drugs under development. Forward-looking Statements This contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance. View original content to download multimedia: SOURCE Brii Biosciences Limited
Yahoo
an hour ago
- Yahoo
Asian Fund Pivots to Samsung Bet After Riding Pop Mart Rally
(Bloomberg) -- A peer-beating Asian equity fund is turning its sights on Samsung Electronics Co. after adding Pop Mart International Group Ltd. before the latter's share price surge. NYC Commutes Resume After Midtown Bus Terminal Crash Chaos Struggling Downtowns Are Looking to Lure New Crowds Massachusetts to Follow NYC in Making Landlords Pay Broker Fees Foreign Buyers Swoop on Cape Town Homes, Pricing Out Locals What Gothenburg Got Out of Congestion Pricing The $1.6 billion Ninety One Global Strategy Fund - Asian Equity Fund bought Pop Mart shares in March 2024 after its quantitative model identified the Labubu maker's earnings potential amid China's economic malaise, said London-based co-manager Charlie Linton. He recently turned overweight on Samsung, saying many investors have 'mispriced' the company because it's lagging rivals like SK Hynix Inc. in the high-bandwidth memory chip market. The fund's screening often highlights stocks that are 'discarded' by investors making decisions based on geographic and sector-driven trends, he said. It has returned 15% this year, outperforming 94% of peers, according to data compiled by Bloomberg. Linton's team relies on a model that screens stocks in the region using a blend of factors — quality, value, operational performance and technical momentum — and picks shares that are expected to withstand market volatility, he said. The fund viewed Pop Mart as undervalued given the popularity of its characters and intellectual property products. Its shares have soared roughly 600% over the past year. While Samsung's shares have trailed those of SK Hynix, which supplies HBM to Nvidia Corp, the firm's next-generation DRAM chip could help the stock catch up with peers once production takes off, Linton said. Samsung shares are up 20% this year, while SK Hynix's have jumped 60%. 'Currently everyone is underweight' Samsung, said Linton, who also owns SK Hynix shares. 'We've taken a bit more positive view, partly because the valuation looks very attractive.' Chinese equities make up almost a third of the fund. Linton owns shares of Naura Technology Group Co., which he sees as a proxy to China's rising semiconductor prowess thanks to its localization efforts and growth that's outpaced domestic counterparts. SNAP Cuts in Big Tax Bill Will Hit a Lot of Trump Voters Too America's Top Consumer-Sentiment Economist Is Worried How to Steal a House China's Homegrown Jewelry Superstar Sperm Freezing Is a New Hot Market for Startups ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Post
2 hours ago
- New York Post
Beijing cannot allow Russia to lose Ukraine war because it wants America distracted, top Chinese diplomat told EU: report
Beijing cannot afford to see Russia lose the Ukraine war, because it needs America focused on the Moscow and Kyiv — and away from the Pacific, China's top diplomat told his EU counterpart, according to a new report. Foreign Minister Wang Yi allegedly shocked European officials at a Brussels meeting Wednesday when he dropped all pretenses and said Russia's invasion of Ukraine has been a blessing for China, sources told the South China Morning Post. Wang touted the three-year war for keeping the US focused on Ukraine, claiming that if the war were to end, Washington would start putting its full attention in the Pacific and could enter into conflict with China. Advertisement 4 Chinese Foreign Minister Wang Yi meeting with EU High Representative Kaja Kallas in Brussels on Wednesday. REUTERS 4 Wang allegedly claimed that Beijing cannot afford to see Russia lose against Ukraine. REUTERS The admission from one of Beijing's top officials, which was not included in either nation's summary of the meeting, came after the EU accused China of assisting in Russia's war effort. The South China Morning Post — Hong Kong's daily newspaper, which is owned by the Alibaba Group — reported the comments. Advertisement Kaja Kallas, EU's high representative for foreign policy, called on China 'to immediately cease all material support that sustains Russia's military industrial complex' and support peace in the Ukraine, according to a statement released by the bloc. The official also 'highlighted the serious threat Chinese companies' support for Russia's illegal war poses to European security.' Beijing maintains that it has not provided any military support to Russia during its invasion of Ukraine, but EU officials claim Chinese companies have given Moscow many of the necessary components needed to build the drones and weapons used in the war. Advertisement 4 Chinese President Xi Jinping has previously said that his partnership with Vladimir Putin has 'no limits.' AP China was one of the nations that failed to condemn Moscow invasion of Ukraine in 2022, with President Xi Jinping standing as an ally of his Russian counterpart Vladimir Putin. While Xi has never publicly called for Beijing to support Russia's war effort, the Chinese leader has previously said their partnership has 'no limits' and blamed the invasion on western aggression. Wednesday's meeting in Brussels also saw the EU demand that China end restrictions on rare earth mineral exports, which Europe warned could endanger the global supply chain. Advertisement 4 The Brussels meeting is set to lay the groundwork for the EU-China summit taking place next month. REUTERS China placed export restrictions on seven rare minerals and magnets — including samarium, gadolinium, terbium, dysprosium, lutetium, scandium, and yttrium — all of which are vital for global defense, energy and automotive sectors. The EU is also urging China to use its influence as Iran's main oil buyer to pressure Tehran to make a deal over its nuclear program to stabilize the Middle East. The meeting was set to lay the groundwork for the summit scheduled for next month between EU and Chinese leaders.
